查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1712507

全球 CRISPR 市場 - 2025-2033

Global CRISPR Market - 2025-2033
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

2024 年全球 CRISPR 市場規模達到 39.3 億美元，預計到 2033 年將達到 159.2 億美元，在 2025-2033 年預測期內的複合年成長率為 16.8%。

CRISPR（成簇的規律間隔的短回文重複序列）是一種基因編輯技術，可以對 DNA 進行精確修改，徹底改變了醫學、農業和生物技術等領域。透過使用 Cas9 酶，CRISPR 使研究人員能夠以驚人的精度添加、刪除或改變遺傳物質。

其應用包括遺傳疾病的基因治療、癌症研究、作物改良和疾病模型的創建。 CRISPR 試劑盒和耗材為研究人員提供了必要的工具，簡化了工作流程並提高了基因編輯實驗的可近性。這些試劑盒在學術和臨床實驗室的應用越來越廣泛，促進了創新。此外，CRISPR 文庫（針對特定基因的引導 RNA 的集合）支持大規模基因功能研究和藥物發現。

市場動態：

駕駛員和約束裝置

基因編輯技術的快速進步

基因編輯技術的快速進步極大地推動了 CRISPR 市場的發展，這些技術為腫瘤學、免疫學和罕見疾病等各個領域提供了更精確、更有效率、更具可擴展性的治療解決方案。這些創新不僅擴大了 CRISPR 的潛在應用，而且還吸引了大型生物製藥公司的大量投資，旨在利用其變革潛力。

例如，2023 年 11 月，阿斯特捷利康宣布向臨床階段生物技術公司 Cellectis 投資 2.45 億美元，作為策略合作的一部分。此次合作旨在利用 Cellectis 專有的基因編輯技術和製造能力來加速下一代治療方法的開發。此次合作將支持新型細胞和基因療法的設計，並強調基因編輯的進步如何鼓勵主要參與者擴大其在 CRISPR 和更廣泛的基因治療領域的影響力。

此外，隨著該技術變得更加精細和普及，它為更多的臨床試驗、在實驗室中的更廣泛應用，甚至在個人化醫療中的應用開闢了機會。這種不斷的創新不僅突破了 CRISPR 所能實現的界限，而且還推動了市場進一步的投資、合作和成長。

先進 CRISPR 工具和技術的高成本

預計先進 CRISPR 工具和技術的高成本將成為 CRISPR 市場成長的重大障礙。雖然該技術前景廣闊，但購買和維護精密設備、試劑和技術人員的費用可能會限制其普及性，特別是對於發展中地區的小型研究機構、新創公司和組織而言。這些資金限制可能會減緩 CRISPR 在學術和商業環境中的採用，阻礙廣泛的實驗、創新和實施。

此外，成本因素可能會延遲臨床應用並限制基於 CRISPR 的治療的可擴展性，尤其是在預算緊張的醫療保健系統中。

目錄

第1章：市場介紹和範圍

  • 報告目標
  • 報告範圍和定義
  • 報告範圍

第2章：高階主管見解與關鍵要點

  • 市場亮點和戰略要點
  • 主要趨勢和未來預測
  • 按產品類型分類的程式碼片段
  • 按應用程式截取的程式碼片段
  • 最終用戶的程式碼片段
  • 按地區分類

第3章：動態

  • 影響因素
    • 驅動程式
      • 基因編輯技術的快速進步。
      • 對個人化和標靶治療的需求不斷增加
    • 限制
      • 先進 CRISPR 工具和技術的高成本
      • 脫靶效應和非預期基因改變的風險
    • 機會
      • 擴大 CRISPR 在藥物研發、診斷和農業領域的應用
    • 影響分析

第4章：戰略洞察與產業展望

  • 市場領導者和先驅者
    • 新興先鋒和傑出參與者
    • 擁有最大銷售品牌的成熟領導者
    • 擁有成熟產品的市場領導者
  • 最新進展與突破
  • 監管和報銷情況
    • 北美洲
    • 歐洲
    • 亞太地區
    • 南美洲
    • 中東和非洲
  • 波特五力分析
  • 供應鏈分析
  • 專利分析
  • SWOT分析
  • 未滿足的需求和差距
  • 市場進入和擴張的推薦策略
  • 情境分析：最佳情況、基本情況和最壞情況預測
  • 定價分析和價格動態

第5章：CRISPR 市場（依產品類型）

  • CRISPR 試劑盒和耗材
  • CRISPR文庫
  • 其他

第6章：CRISPR 市場（按應用）

  • 藥物研發
  • 農業
  • 其他

第7章：CRISPR 市場（以最終用戶分類）

  • 製藥公司
  • 生技公司
  • 學術及研究機構
  • 其他

第8章：CRISPR 市場，按區域市場分析和成長機會

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 歐洲其他地區
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地區
  • 亞太
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 中東和非洲

第9章：競爭格局與市場定位

  • 競爭概況和主要市場參與者
  • 市佔率分析與定位矩陣
  • 策略夥伴關係、併購
  • 產品組合和創新的關鍵發展
  • 公司基準化分析

第10章：公司簡介

  • Thermo Fisher Scientific, Inc.
    • 公司概況
    • 產品組合
      • 產品描述
      • 產品關鍵績效指標 (KPI)
      • 歷史和預測產品銷售
      • 產品銷售量
    • 財務概覽
      • 公司收入
      • 地區收入佔有率
      • 收入預測
    • 關鍵進展
      • 併購
      • 關鍵產品開發活動
      • 監管部門批准等
    • SWOT分析
  • Merck KGaA
  • Agilent Technologies, Inc.
  • GenScript
  • Creative Biogene
  • Bio-Rad Laboratories, Inc.
  • Takara Bio Inc.
  • QIAGEN
  • Eurofins Genomics
  • Synthego

第 11 章：假設與研究方法

  • 資料收集方法
  • 數據三角測量
  • 預測技術
  • 數據驗證和確認

第 12 章：附錄

簡介目錄
Product Code: BT9502

The global CRISPR market reached US$ 3.93 billion in 2024 and is expected to reach US$ 15.92 billion by 2033, growing at a CAGR of 16.8% during the forecast period 2025-2033.

CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a gene-editing technology that allows precise modifications to DNA, revolutionizing fields such as medicine, agriculture, and biotechnology. By using the Cas9 enzyme, CRISPR enables researchers to add, remove, or alter genetic material with remarkable accuracy.

Its applications include gene therapy for genetic disorders, cancer research, crop improvement, and the creation of disease models. CRISPR kits and consumables provide essential tools for researchers, simplifying workflows and enhancing the accessibility of gene-editing experiments. These kits are increasingly used across academic and clinical labs, fostering innovation. Additionally, CRISPR libraries, which are collections of guide RNAs targeting specific genes, support large-scale gene function studies and drug discovery.

Market Dynamics: Drivers & Restraints

Rapid Advancements in Gene Editing Technologies

The CRISPR market is being significantly driven by rapid advancements in gene editing technologies, which are enabling more precise, efficient, and scalable therapeutic solutions across various fields, such as oncology, immunology, and rare diseases. These innovations are not only expanding the potential applications of CRISPR but are also attracting substantial investments from major biopharmaceutical companies aiming to harness its transformative potential.

For instance, in November 2023, AstraZeneca announced a $245 million investment in Cellectis, a clinical-stage biotechnology company, as part of a strategic collaboration. This partnership aims to accelerate the development of next-generation therapeutics by leveraging Cellectis' proprietary gene editing technologies and manufacturing capabilities. The collaboration will support the design of novel cell and gene therapies, highlighting how advancements in gene editing are encouraging major players to expand their presence in the CRISPR and broader gene therapy space.

Additionally, as the technology becomes more refined and accessible, it opens up opportunities for more clinical trials, broader adoption in labs, and even use in personalized medicine. This constant innovation not only pushes the boundaries of what CRISPR can achieve but also fuels further investment, collaboration, and growth within the market.

High Costs Associated with Advanced CRISPR Tools and Technologies

The high costs associated with advanced CRISPR tools and technologies are expected to act as a significant barrier to the growth of the CRISPR market. While the technology holds immense promise, the expense involved in acquiring and maintaining sophisticated equipment, reagents, and skilled personnel can limit its accessibility, especially for smaller research institutions, startups, and organizations in developing regions. These financial constraints may slow down the adoption of CRISPR in both academic and commercial settings, hindering widespread experimentation, innovation, and implementation.

Additionally, the cost factor can delay clinical applications and limit the scalability of CRISPR-based treatments, particularly in healthcare systems with tight budgets.

Segment Analysis

The global CRISPR market is segmented based on product type, application, end-user, and region.

Product Type:

CRISPR kits & consumables in the product type segment are expected to dominate the CRISPR market.

The CRISPR kits and consumables segment is expected to hold a dominant share of the market, largely due to their essential role in gene editing research and growing demand across academic, clinical, and industrial settings. These kits provide researchers with ready-to-use tools that simplify complex CRISPR workflows, making the technology more accessible and efficient.

As more laboratories and institutions adopt CRISPR for various applications, from genetic disease research to agricultural improvements, the need for high-quality, reliable kits and consumables continues to rise. Their recurring use in experiments and routine lab work also ensures steady demand, positioning this segment as a key driver of growth in the CRISPR market.

With the growing need and demand for these kits and consumables are being innovated by the market players are innovating to meet the growing demand. For instance, in March 2024, Carolina Biological Supply Company announced an exclusive partnership with the ChristianaCare Gene Editing Institute to produce and distribute the CRISPR in a Box educational kit. Designed for high school students (grades 9-12) and higher education, this affordable, hands-on lab kit includes printed materials and interactive exercises. It offers students an engaging introduction to CRISPR gene editing.

Geographical Analysis

North America is expected to dominate the global CRISPR market.

North America is anticipated to lead the CRISPR space in the coming years, driven by a strong foundation of advanced biotechnology infrastructure, significant investments in genetic research, and supportive regulatory frameworks. The region has a large number of the world's leading biotech companies, academic institutions, and research organizations that are actively exploring CRISPR-based technologies for applications ranging from disease treatment to agriculture.

The growing number of clinical trials utilizing CRISPR technology is significantly boosting demand and driving the CRISPR market in North America. For instance, in September 2024, KSQ Therapeutics (US) recently received FDA clearance for its IND application for KSQ-004EX, a CRISPR-Cas9 engineered tumor-infiltrating lymphocyte (TIL) therapy.

This approval allows the initiation of a Phase 1/2 clinical trial, sponsored by The University of Texas MD Anderson Cancer Center, to evaluate the therapy's safety and efficacy in patients with advanced solid tumors. The increasing clinical validation of CRISPR-based therapies like KSQ-004EX highlights the growing momentum of gene editing in oncology and its expanding role in shaping the North America CRISPR market.

Competitive Landscape

The global market players in the CRISPR market include Thermo Fisher Scientific, Inc., Merck KGaA, Agilent Technologies, Inc., GenScript, Creative Biogene, Bio-Rad Laboratories, Inc., Takara Bio Inc., QIAGEN, Eurofins Genomics, and Synthego, among others.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming pharmaceutical advancements.
  • Type Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient Type delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global CRISPR market report will provide approximately 45 tables, 46 figures, and 180 pages.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Product Type
  • 2.4. Snippet by Application
  • 2.5. Snippet by End-User
  • 2.6. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Rapid Advancements in Gene Editing Technologies.
      • 3.1.1.2. Increasing Demand for Personalized and Targeted Therapies
    • 3.1.2. Restraints
      • 3.1.2.1. High costs Associated with Advanced CRISPR Tools and Technologies
      • 3.1.2.2. Risk of off-target Effects and Unintended Genetic Changes
    • 3.1.3. Opportunity
      • 3.1.3.1. Expanding Use of CRISPR in Drug Discovery, Diagnostics, and Agriculture
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established leaders with largest selling Brand
    • 4.1.3. Market leaders with established Product
  • 4.2. Latest Developments and Breakthroughs
  • 4.3. Regulatory and Reimbursement Landscape
    • 4.3.1. North America
    • 4.3.2. Europe
    • 4.3.3. Asia Pacific
    • 4.3.4. South America
    • 4.3.5. Middle East & Africa
  • 4.4. Porter's Five Forces Analysis
  • 4.5. Supply Chain Analysis
  • 4.6. Patent Analysis
  • 4.7. SWOT Analysis
  • 4.8. Unmet Needs and Gaps
  • 4.9. Recommended Strategies for Market Entry and Expansion
  • 4.10. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.11. Pricing Analysis and Price Dynamics

5. CRISPR Market, By Product Type

  • 5.1. Introduction
    • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 5.1.2. Market Attractiveness Index, By Product Type
  • 5.2. CRISPR kits & Consumables*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 5.3. CRISPR Libraries
  • 5.4. Others

6. CRISPR Market, By Application

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 6.1.2. Market Attractiveness Index, By Application
  • 6.2. Drug Discovery & Development*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Agriculture
  • 6.4. Others

7. CRISPR Market, By End-User

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 7.1.2. Market Attractiveness Index, By End-User
  • 7.2. Pharmaceutical Companies*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Biotechnology Companies
  • 7.4. Academic & Research Institutes
  • 7.5. Others

8. CRISPR Market, By Regional Market Analysis and Growth Opportunities

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 8.1.2. Market Attractiveness Index, By Region
  • 8.2. North America
    • 8.2.1. Introduction
    • 8.2.2. Key Region-Specific Dynamics
    • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.2.6.1. U.S.
      • 8.2.6.2. Canada
      • 8.2.6.3. Mexico
  • 8.3. Europe
    • 8.3.1. Introduction
    • 8.3.2. Key Region-Specific Dynamics
    • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.3.6.1. Germany
      • 8.3.6.2. U.K.
      • 8.3.6.3. France
      • 8.3.6.4. Spain
      • 8.3.6.5. Italy
      • 8.3.6.6. Rest of Europe
  • 8.4. South America
    • 8.4.1. Introduction
    • 8.4.2. Key Region-Specific Dynamics
    • 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.4.6.1. Brazil
      • 8.4.6.2. Argentina
      • 8.4.6.3. Rest of South America
  • 8.5. Asia-Pacific
    • 8.5.1. Introduction
    • 8.5.2. Key Region-Specific Dynamics
    • 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.5.6.1. China
      • 8.5.6.2. India
      • 8.5.6.3. Japan
      • 8.5.6.4. South Korea
      • 8.5.6.5. Rest of Asia-Pacific
  • 8.6. Middle East and Africa
    • 8.6.1. Introduction
    • 8.6.2. Key Region-Specific Dynamics
    • 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9. Competitive Landscape and Market Positioning

  • 9.1. Competitive Overview and Key Market Players
  • 9.2. Market Share Analysis and Positioning Matrix
  • 9.3. Strategic Partnerships, Mergers & Acquisitions
  • 9.4. Key Developments in Product Portfolios and Innovations
  • 9.5. Company Benchmarking

10. Company Profiles

  • 10.1. Thermo Fisher Scientific, Inc.*
    • 10.1.1. Company Overview
    • 10.1.2. Product Portfolio
      • 10.1.2.1. Product Description
      • 10.1.2.2. Product Key Performance Indicators (KPIs)
      • 10.1.2.3. Historic and Forecasted Product Sales
      • 10.1.2.4. Product Sales Volume
    • 10.1.3. Financial Overview
      • 10.1.3.1. Company Revenue
      • 10.1.3.2. Geographical Revenue Shares
      • 10.1.3.3. Revenue Forecasts
    • 10.1.4. Key Developments
      • 10.1.4.1. Mergers & Acquisitions
      • 10.1.4.2. Key Product Development Activities
      • 10.1.4.3. Regulatory Approvals, etc.
    • 10.1.5. SWOT Analysis
  • 10.2. Merck KGaA
  • 10.3. Agilent Technologies, Inc.
  • 10.4. GenScript
  • 10.5. Creative Biogene
  • 10.6. Bio-Rad Laboratories, Inc.
  • 10.7. Takara Bio Inc.
  • 10.8. QIAGEN
  • 10.9. Eurofins Genomics
  • 10.10. Synthego

LIST NOT EXHAUSTIVE

11. Assumption and Research Methodology

  • 11.1. Data Collection Methods
  • 11.2. Data Triangulation
  • 11.3. Forecasting Techniques
  • 11.4. Data Verification and Validation

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us